Jump to content
  • charter.png
    Charter

     

    The purpose of the Rosacea Research & Development Institute [RRDi] is to fund research and development for finding a cure for rosacea by establishing a Medical Advisory Committee [MAC] of the best available minds on rosacea and to publish the results of this endeavor to the public and professional groups. This MAC will provide the direction of the research. Research may also include studying various treatments for the control of rosacea in multi-center, double blind, placebo controlled clinical trial studies. The RRDi is commited to support patient advocacy for those suffering from rosacea. This organization is open to the public and membership is free and has been organized by rosaceans for rosaceans. This organization is a non-profit corporation registered in the State of Hawaii and 501 (c) (3) tax-exempt status approval has been obtained from the IRS effective June 7, 2004. The Articles of Incorporation, the Bylaws, and the Conflict of Interest Policy are available for the public.

     

    Membership is open to the public and is free. Rosaceans are specially invited to join. All who join become members of the corporation and for now this number is not limited but may be revised in the future by the institute. There are two categories of members: 

    Voting Member (a member who choses voluntarily to provide contact information such as first and last name, mailing address and phone number, email addresses)

    Non Voting Member (a member who only provides one email address)

    A rosacean is anyone who is diagnosed by a physician as having rosacea. All that is necessary to be designated a voting member is a statement from the member that a diagnosis of rosacea has been obtained from a physician as well as the contact information mentioned above for voting members. Voting members should be rosacea sufferers (rosaceans). 

    Non-rosaceans are permitted to join and should identify themselves as such upon demand from the institute. Non-rosaceans are those who have not obtained a diagnosis of rosacea by a physician. 

    Any member of the institute may be removed from the membership at any time at the sole discretion of the institute. Rules of the institute are published and available to the public. Violation of the rules may be grounds for termination as a member of the institute. Membership in the institute is a privilege.

    Funding will provide a rosacea MAC of the best available minds on finding a cure for this disease. The selection of who is chosen to be in this MAC will be based on not only the qualifications of the individual but also from nominations by both rosacean and non rosaceans members of the institute.

    Sources of funding to the institute will be publicized including the name of the donor unless the donor requests anonymity. Expenses of the institute will be publicized down to the last cent, showing where all the spending went and for what purpose since transparency is a core principle of our non profit organization. 

    The philosophy and spirit of this institute is that funding should predominately be used for research and development and not for the administration of the institute. Volunteers are an integral part of this spirit and we hope to include member rosaceans and non-rosaceans who are willing to help the purpose of the institute become a reality. We need your help to find a cure for rosacea, to research rosacea, to publish the findings of this research and provide a MAC of the best available minds on rosacea. The views and suggestions of rosaceans will be an integral part in directing the research on rosacea, in choosing the MAC and the directors of the institute. Voting members of the institute will have a voice in the decision making of the institute, although directors of the institute will make all final decisions.

    Members of the institute will not profit from the institute however the Medical Advisory Committee members or members may be compensated for services rendered to the institute.

    Members will elect a board of directors which will include:

    Director, Assistant Director, Secretary, Treasurer and other board members. The board of directors will decide all matters of the institute and will be volunteers.

    Funding on rosacea research by the RRDi will not be used on animal testing.

    Our Mission Statement may be read by clicking here.

    This charter may be revised from time to time by the institute when deemed appropriate at the sole discretion of the institute.

  • Posts

    • Surgical Treatment Strategy for Severe Rhinophyma With Bilateral Pedicled Nasolabial Flaps. J Craniofac Surg. 2019 Apr 12;: Authors: Cui MY, Guo S, Wang CC, Lv MZ, Jin SF Abstract BACKGROUND: Rhinophyma is a rare disease characterized by chronic inflammation and hypertrophy of sebaceous glands, blood vessels, and fibrous tissue, associated with end-stage severe acne rosacea. There are multiple approaches to treatment and repair, including dermal shaving, secondary intention healing, free skin graft, and skin flaps. However, these methods have various disadvantages, such as prolonged healing, obvious scarring, and skin texture mismatch. Therefore, the authors adopted surgical excision with bilateral pedicled nasolabial flaps, which have better color, texture, thickness, and symmetry. METHODS: The authors present a case of severe nasal tip rhinophyma successfully treated by excision and repair with bilateral pedicled nasolabial flaps. This procedure combines deep excision of the focal lesion and coverage with bilateral nasolabial flaps. RESULTS: The bilateral pedicled nasolabial flaps were used for severe rhinophyma in a patient. After the operation, the flaps survived uneventfully in this study. Both functional and aesthetic results were satisfactory at 3 months. CONCLUSION: The authors offer an effective method for surgical treatment of rhinophyma. Excision of hypertrophic nasal tissue is an acknowledged effective treatment for patients with severe rhinophyma. After excision, reconstruction with nasolabial flaps results in satisfactory outcomes both functionally and aesthetically. Therefore, this approach should be considered an appropriate alternative in cases of severe rhinophyma. PMID: 30998589 [PubMed - as supplied by publisher] {url} = URL to article
    • A detailed report on cannabinoid signaling in the skin had this to say:  "It has recently been shown that abuse of synthetic, hyperpotent cannabinoids (e.g., “Bonsai”, “fake weed”, “K2”, and “Jamaica”) can result in dermatological disorders, such as premature skin aging, hair loss and graying, or acne [88], indicating that cannabinoid signaling can profoundly influence skin biology." "Importantly, with respect to the efficiency of PEA, human clinical data are also available. Indeed, the PEA containing Physiogel® A.I. Cream was found to alleviate itch in 14 out of 22 patients suffering from prurigo, lichen simplex and other pruritic diseases. Importantly, the same formulation was found to be effective in alleviating erythema, excoriation, scaling, lichenification, dryness, as well as pruritus in AD patients (ATOPA study). However, another vehicle controlled, randomized clinical trial involving a total of 100 subjects suffering from pruritic dry skin (ClinicalTrials.gov ID: NCT00663364) found that a PEA containing lotion was not significantly superior in alleviating itch as compared to its emollient vehicle." PEA is Palmitamide MEA, a naturally occurring lipid compound that may act as an anti-oxidant and anti-irritant. Molecules. 2019 Mar; 24(5): 918. Published online 2019 Mar 6. doi: 10.3390/molecules24050918 Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System Kinga Fanni Tóth, Dorottya Ádám, Tamás Bíró, Attila Oláh
    • Related Articles [The value of reflectance confocal microscopy in detection of Demodex mites]. Ann Dermatol Venereol. 2017 Jun - Jul;144(6-7):459-461 Authors: Harmelin Y, Le Duff F, Passeron T, Lacour JP, Bahadoran P PMID: 28347561 [PubMed - indexed for MEDLINE] {url} = URL to article
    • A sample of food-grade diatomaceous Earth  Courtesy of Wikimedia Commons Diatomaceous earth - also known as D.E., diatomite, or kieselgur/kieselguhr – is a naturally occurring, soft, siliceous sedimentary rock that is easily crumbled into a fine white to off-white powder. Wikipedia Can it be used to treat demodectic rosacea?  At least one person thinks so.  This was posted initially at Facebook, Rosacea Tips and Support Group, by Karli Walton who writes, "People are using horsepaste (ivermectin) for their mites, ivermectin is also in sooIantra. I haven’t tried either. You can also use diatomaceous earth powder mixed with honey. I use the powder on my dogs for their mites and fleas. It’s natural and won’t hurt you. Just keep in mind with any of these things, that it will get better before it gets worse. When you put it on, the mites start freaking out before they die." Karli probably meant it 'gets worse before it gets better.' Without a doubt, since it was posted on Facebook, others will try this and we receive more reports  since you can obtain food grade diatomaceous earth below and other mediums besides honey will be attempted and the results will be coming in. 
    • Related Articles Do Dermatologic Diagnosis Change in Hot vs. Cold Periods of The Year? A Sub-Analysis of the DIADERM National Sample (Spain 2016). Actas Dermosifiliogr. 2019 Apr 11;: Authors: Gonzalez-Cantero A, Arias-Santiago S, Buendía-Eisman A, Molina-Leyva A, Gilaberte Y, Fernández-Crehuet P, Husein-ElAhmed H, Viera-Ramírez A, Fernández-Peñas P, Taberner R, Descalzo MA, García-Doval I Abstract BACKGROUND: Knowledge of seasonal variation of cutaneous disorder may be useful for heath planning and disease management. To date, however, descriptions of seasonality including all diagnoses in a representative country sample are very scarce. OBJECTIVES: To evaluate if clinical dermatologic diagnosis in Spain change in the hot vs. cold periods. MATERIALS AND METHODS: Survey based on a random sample of dermatologists in Spain, stratified by area. Each participant collected data during 6 days of clinical activity in 2016 (3 in the cold period of the year, 3 in the hot period). Clinical diagnoses were coded using ICD-10. RESULTS: With a 62% response proportion, we got data on 10999 clinical diagnoses. ICD-10 diagnostic groups that showed changes were: other benign neoplasms of skin (D23), rosacea (L71) and other follicular disorders (L73), which were more common in the hot period and acne (L70) which was more frequent in the cold period. We describe differences in the paediatric population and in private vs. public practice. Some of these differences might be associated to differences in the population demanding consultations in different periods. CONCLUSIONS: The frequency of most clinical diagnosis made by dermatologists does not change over the year. Just a few of the clinical diagnoses made by dermatologists show a variation in hot vs. cold periods. These variations could be due to the diseases themselves or to seasonal changes in the demand for consultation. PMID: 30982569 [PubMed - as supplied by publisher] {url} = URL to article
×
×
  • Create New...